PE20160839A1 - Derivados de 4-azaindol - Google Patents

Derivados de 4-azaindol

Info

Publication number
PE20160839A1
PE20160839A1 PE2016000374A PE2016000374A PE20160839A1 PE 20160839 A1 PE20160839 A1 PE 20160839A1 PE 2016000374 A PE2016000374 A PE 2016000374A PE 2016000374 A PE2016000374 A PE 2016000374A PE 20160839 A1 PE20160839 A1 PE 20160839A1
Authority
PE
Peru
Prior art keywords
halogen
alkyl
azaindol
compounds
hydroxyclohexyl
Prior art date
Application number
PE2016000374A
Other languages
English (en)
Inventor
Louise Michelle Birch
Alan James Braunton
Pineiro Jose Luis Castro
Motohiro Soejima
James Edward Kitulagoda
Andrew Payne
Afzal Khan
Original Assignee
Eisai Randd Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Randd Man Co Ltd filed Critical Eisai Randd Man Co Ltd
Publication of PE20160839A1 publication Critical patent/PE20160839A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 4-AZAINDOL DE FORMULAS (IA) Y (IB) DONDE R1 ES H, HALOGENO, CN, ENTRE OTROS; R2 ES H; p ES 1 O 2; R4 ES HALOGENO, ALQUILO C1-C4, ALCOXI C1-C4, ENTRE OTROS, EN LA FORMULA (IA); Y PARA LA FORMULA (IB) R1 ES ALQUILO C1-C4, ALCOXI C1-C4, ENTRE OTROS; R2 ES H; R4a ES H O HALOGENO; R4b ES H, HALOGENO, ALQUILO C1-C4, ENTRE OTROS; R4c ES H, HALOGENO, HALOALQUILO C1-C4, ENTRE OTROS; R4d ES H O HALOGENO. SON COMPUESTOS PREFERIDOS: 1-(4-FLUOROBENCIL)-N-((1S-2S)-2-HIDROXICICLOHEXIL)-7-METIL-1H-PIRROL[3,2-b]PIRIDINA-3-CARBOXAMIDA; 1-(3-FLUOROBENCIL)-N-((1S-2S)-2-HIDROXICICLOHEXIL)-1H-PIRROL[3,2-b]PIRIDINA-3-CARBOXAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL RECEPTOR DE ACETILCOLINA MUSCARINICO M1 (mAChR) SIENDO UTILES EN EL TRATAMIENTO DE DEMENCIA TIPO ALZHEIMER
PE2016000374A 2013-10-01 2014-09-30 Derivados de 4-azaindol PE20160839A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1317363.8A GB201317363D0 (en) 2013-10-01 2013-10-01 Novel compounds

Publications (1)

Publication Number Publication Date
PE20160839A1 true PE20160839A1 (es) 2016-08-20

Family

ID=49585123

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000374A PE20160839A1 (es) 2013-10-01 2014-09-30 Derivados de 4-azaindol

Country Status (21)

Country Link
US (3) US20150094328A1 (es)
EP (2) EP3489237B1 (es)
JP (3) JP6517790B2 (es)
KR (1) KR102248559B1 (es)
CN (1) CN105873927B (es)
AR (1) AR097866A1 (es)
AU (1) AU2014330880B2 (es)
BR (1) BR112016007016A8 (es)
CA (1) CA2924619C (es)
CL (1) CL2016000726A1 (es)
ES (2) ES2710190T3 (es)
GB (1) GB201317363D0 (es)
HK (1) HK1223090A1 (es)
IL (1) IL244609B (es)
MX (1) MX368956B (es)
PE (1) PE20160839A1 (es)
PH (1) PH12016500529A1 (es)
RU (1) RU2688938C2 (es)
SG (1) SG11201602052YA (es)
TW (1) TW201546070A (es)
WO (1) WO2015049574A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
NZ725921A (en) 2014-04-23 2023-09-29 Takeda Pharmaceuticals Co Isoindoline-1-one derivatives as cholinergic muscarinic m1 receptor positive alloesteric modulator activity for the treatment of alzheimers disease
JP6531093B2 (ja) 2014-05-16 2019-06-12 武田薬品工業株式会社 含窒素複素環化合物
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
MD3303331T2 (ro) * 2015-06-08 2019-05-31 Suven Life Sciences Ltd Modulatori alosterici pozitivi ai receptorilor muscarinici M1
CA2997956C (en) * 2015-09-10 2019-10-29 Suven Life Sciences Limited Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
CA3014791A1 (en) 2016-02-16 2017-08-24 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
US10899759B2 (en) 2016-09-30 2021-01-26 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
US11234979B2 (en) 2017-10-18 2022-02-01 Suven Life Sciences Limited Heteroaryl compounds as muscarinic M1 receptor positive allosteric modulators
CA3078164C (en) * 2017-10-27 2022-11-15 Suven Life Sciences Limited Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
KR102347368B1 (ko) * 2020-11-03 2022-01-07 (주)케이메디켐 신규한 아자인돌 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
US6063930A (en) 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
WO2003044018A1 (en) 2001-11-19 2003-05-30 Neurogen Corporation 1h-pyrrolo[3,2-b]pyridine-3-carboxylic acid amides
GB0222743D0 (en) 2002-10-01 2002-11-06 Celltech R&D Ltd Chemical compounds
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
EP1615698B1 (en) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
WO2004089415A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
US9271963B2 (en) 2005-03-03 2016-03-01 Universitat Des Saarlandes Selective inhibitors of human corticosteroid synthases
FR2890072A1 (fr) * 2005-09-01 2007-03-02 Fournier S A Sa Lab Nouveaux composesde pyrrolopyridine
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
US7964728B2 (en) 2006-07-06 2011-06-21 Solvay Pharmaceuticals B.V. Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
JP2010511632A (ja) 2006-11-30 2010-04-15 アミラ ファーマシューティカルス，インコーポレーテッド ５−リポキシゲナーゼ活性化タンパク質インヒビターおよび一酸化窒素モジュレーターを含んでいる組成物および治療法
EA020332B1 (ru) 2007-08-10 2014-10-30 Х. Лундбекк А/С Аналоги гетероариламидов
WO2009032125A1 (en) 2007-08-29 2009-03-12 Schering Corporation 2,3-substituted azaindole derivatives for treating viral infections
CA2711487A1 (en) 2008-01-25 2009-07-30 Merck Sharp & Dohme Corp. Quinolizidinone m1 receptor positive allosteric modulators
ES2430621T3 (es) 2008-01-31 2013-11-21 Sanofi Azaindol-3-carboxamidas cíclicas, su preparación y su uso como productos farmacéuticos
WO2009121033A2 (en) 2008-03-27 2009-10-01 University Of Southern California Substituted nitrogen heterocycles and synthesis and uses thereof
AU2009231258A1 (en) 2008-04-04 2009-10-08 Biomarin Iga Limited Compounds for treating muscular dystrophy
US8012992B2 (en) 2008-06-30 2011-09-06 Allergan, Inc. Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
AU2009283195A1 (en) 2008-08-18 2010-02-25 Yale University MIF modulators
WO2010033980A2 (en) 2008-09-22 2010-03-25 Isis Innovation Ltd. 4-azaindole bisphosphonates
EP2358686B1 (en) 2008-11-20 2012-09-26 Merck Sharp & Dohme Corp. Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
BRPI0922937A2 (pt) 2008-12-05 2019-09-24 Hoffmann La Roche inibidores de pirrolopirazinil uréia quinase
EP2370407B1 (en) 2008-12-19 2014-06-18 Bristol-Myers Squibb Company Carbazole and carboline kinase inhibitors
CA2750708A1 (en) 2009-02-23 2010-08-26 Merck Sharp & Dohme Corp. Pyrazolo [4,3-c] cinnolin-3-one m1 receptor positive allosteric modulators
WO2010123716A1 (en) 2009-04-20 2010-10-28 Merck Sharp & Dohme Corp. Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
JP2012211085A (ja) 2009-08-12 2012-11-01 Kyowa Hakko Kirin Co Ltd ヘッジホッグシグナル阻害剤
WO2011023696A1 (en) * 2009-08-26 2011-03-03 Nycomed Gmbh Methylpyrrolopyridinecarboxamides
CA2770480C (en) 2009-08-31 2014-11-18 Merck Sharp & Dohme Corp. Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
EP2512245B1 (en) 2009-12-14 2014-07-23 Merck Sharp & Dohme Corp. Pyridoquinazolinone m1 receptor positive allosteric modulators
DK2512243T3 (en) * 2009-12-17 2016-07-25 Merck Sharp & Dohme POSITIVE ALLOSTERIC QUINOLINAMIDE M1 RECEPTOR MODULATORS
WO2011084371A1 (en) 2009-12-21 2011-07-14 Merck Sharp & Dohme Corp. Aminobenzoquinazolinone m1 receptor positive allosteric modulators
CN102770431A (zh) 2009-12-23 2012-11-07 赛诺菲 [4[4-(5-氨基甲基-2-氟-苯基)-哌啶-1-基]-(1h-吡咯并吡啶-基)-甲酮及其合成
EP2575454B1 (en) 2010-05-28 2018-08-29 Merck Sharp & Dohme Corp. Naphthalene carboxamide m1 receptor positive allosteric modulators
US8557992B2 (en) * 2010-06-15 2013-10-15 Merck Sharp & Dohme Corp. Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators
EP2582676B1 (en) 2010-06-15 2016-12-14 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide m1 receptor positive allosteric modulators
US8697690B2 (en) 2010-07-01 2014-04-15 Merck Sharp & Dohme Corp. Isoindolone M1 receptor positive allosteric modulators
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
EP2624697B1 (en) 2010-10-04 2015-11-25 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
ES2716865T3 (es) 2011-02-18 2019-06-17 Scripps Research Inst Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012154888A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
EP2709621B1 (en) 2011-05-17 2016-11-02 Merck Sharp & Dohme Corp. N-linked quinolineamide m1 receptor positive allosteric modulators
EP2709451B1 (en) 2011-05-17 2015-12-30 Merck Sharp & Dohme Corp. N-linked lactam m1 receptor positive allosteric modulators
WO2012158473A1 (en) * 2011-05-17 2012-11-22 Merck Sharp & Dohme Corp. N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
EP3639823A1 (en) 2011-10-28 2020-04-22 Vanderbilt University Center for Technology Transfer and Commercialization Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m1
CA2860008C (en) 2011-12-22 2020-11-10 Dominique Swinnen Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
WO2013106795A1 (en) * 2012-01-12 2013-07-18 Vanderbilt University Substituted 4-(1h~pyrazol-4.yl)benzyl analogues as positive allosteric modulators of machr m1 receptors
WO2015009525A1 (en) * 2013-07-17 2015-01-22 Global Alliance For Tb Drug Development Azaindole compounds, synthesis thereof, and methods of using the same
TW201512197A (zh) * 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
WO2015044072A1 (en) * 2013-09-27 2015-04-02 F. Hoffmann-La Roche Ag Indol and indazol derivatives
GB201317363D0 (en) * 2013-10-01 2013-11-13 Eisai Ltd Novel compounds

Also Published As

Publication number Publication date
KR102248559B1 (ko) 2021-05-04
RU2688938C2 (ru) 2019-05-23
WO2015049574A1 (en) 2015-04-09
HK1223090A1 (zh) 2017-07-21
CN105873927B (zh) 2017-11-28
SG11201602052YA (en) 2016-04-28
CA2924619A1 (en) 2015-04-09
BR112016007016A8 (pt) 2020-02-27
IL244609A0 (en) 2016-04-21
KR20160072133A (ko) 2016-06-22
JP6517790B2 (ja) 2019-05-22
GB201317363D0 (en) 2013-11-13
CA2924619C (en) 2021-12-07
RU2016116775A3 (es) 2018-06-27
US20160244445A1 (en) 2016-08-25
JP2019112433A (ja) 2019-07-11
US20180208593A1 (en) 2018-07-26
EP3489237B1 (en) 2020-05-13
ES2710190T3 (es) 2019-04-23
MX2016004014A (es) 2016-09-21
MX368956B (es) 2019-10-23
AU2014330880A1 (en) 2016-04-07
US20150094328A1 (en) 2015-04-02
JP2016531890A (ja) 2016-10-13
EP3052496B1 (en) 2018-11-28
CL2016000726A1 (es) 2016-09-23
EP3052496A1 (en) 2016-08-10
CN105873927A (zh) 2016-08-17
BR112016007016A2 (pt) 2017-08-01
ES2807221T3 (es) 2021-02-22
TW201546070A (zh) 2015-12-16
EP3489237A1 (en) 2019-05-29
JP2020143100A (ja) 2020-09-10
JP6899944B2 (ja) 2021-07-07
AU2014330880B2 (en) 2019-01-31
US9926312B2 (en) 2018-03-27
AR097866A1 (es) 2016-04-20
PH12016500529A1 (en) 2016-05-16
RU2016116775A (ru) 2017-11-09
IL244609B (en) 2019-12-31
US10072005B2 (en) 2018-09-11

Similar Documents

Publication Publication Date Title
PE20160839A1 (es) Derivados de 4-azaindol
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
CY1120521T1 (el) Παρασκευασμα προμειγματος δεξμεδετομιδινης
PE20130306A1 (es) Morfolinopirimidinas y su uso en terapia
ES2521596T3 (es) Combinación del compuesto GlyT1 con antipsicóticos
PE20141308A1 (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
PE20160521A1 (es) Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromatico-bencil-amida
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
AR092269A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
PE20152033A1 (es) Heterociclos bicicliclos como inhibidores de fgfr
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
PE20140250A1 (es) Derivados de piperidina puenteada
AR056103A1 (es) Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1
ES2721018T3 (es) N-Acil-(3-sustituido)-(8-metil)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor NK-3, composición farmacéutica, métodos para su uso en trastornos mediados por el receptor de NK-3
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
PE20151060A1 (es) Nuevos derivados de pirazina como agonistas del receptor cb2
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
PE20091035A1 (es) Derivados de 2-aminopirimidina
AR091781A1 (es) Antagonistas del receptor de 5-ht3
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt

Legal Events

Date Code Title Description
FD Application declared void or lapsed